SlideShare a Scribd company logo
5
Most read
6
Most read
7
Most read
EVALUATION
OF
MICROENCAPSULATION
PRESENTED BY :_
MR. ANURAG PDY (B.PHARM)
SUBMITTED TO :_
MR.VIPIN AGARWAL
ASSOCIATE PROFESSOR
AT
(INVERTIS INSTITUTE OF PHARMACY)
INTRODUCTION
Microencapsulation is one of the most interesting modes of drug delivery systems.
It is an interdisciplinary field that requires knowledge of field of pure polymer science, familiarity in emulsion
technology and an in-depth understanding of drug and protein stabilization.
It is a process in which very tiny droplets or particles of liquid or solid material are surrounded or coated with a
continuous film of polymeric material, ranging in size from 1 to 5,000 microns.
This technique is mainly used for taste masking of bitter drugs, formulation of controlled release and sustained
action dosage forms, separation of incompatible materials, protection of moisture and light sensitive drugs.
Diclofenac sodium (DS) is a Non-steroidal anti-inflammatory drug (NSAID) belongs to the group of aryl acetic acid
derivative.
It is widely used in treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.
Because of its short biological half-life (2 hrs.), it is eliminated from plasma compartments of the body within few
hours, so frequent administration is necessary to maintain its therapeutic concentration.
Evaluation of sustained release
microcapsules containing Diclofenac sodium
(Continued…….)
It also known that repeated oral administration of DS in the large doses causes gastrointestinal disturbances,
peptic ulcer and bleeding.
The usual therapeutic dose and dosing frequency of conventional DS tablets is high, because of the short
biological half-life of the drug (2 hrs.); makes it an ideal candidate for modified release dosage forms.
To reduce the frequency of administrations and to improve patient compliances, once daily sustained release
dosage forms of DS is desirable.
The choice of the methods for the preparation of microcapsules depends on many factors such as the drug
solubility, partition co-efficiency, polymer composition, molecular weight etc.
For instance, emulsion solvent evaporation technique may be a method of choice for the preparation of
microspheres of water insoluble drugs.
In the emulsion solvent evaporation method, the water insoluble drug and polymer are dissolved in an organic
phase, emulsified to form an o/w emulsion, evaporated the organic phase and the microcapsules so formed are
filtered and dried.
Since Diclofenac is a water insoluble drug, emulsion solvent evaporation technique is selected for the preparation
of sustained release microcapsules
2. MATERIALS AND METHODS
2.1. Materials
Ethyl cellulose, sodium carboxyl methyl cellulose, chloroform, hydrochloric acid and methanol.
All reagents used were of analytical reagent grade.
Double distilled water was used for all the experiments.
2.2. Preparation of DS microcapsules
DS microcapsules were prepared by emulsion solvent evaporation technique by employing the
chloroform as solvent and ethyl cellulose as a polymer with a core: coat ratio of 1:1, 2:3 and 2:1.
The polymer (1, 1.5 and 0.5 g) was dissolved in chloroform (25 mL) to form a homogeneous
polymer solution.
Core material DS (1 g) was added to the polymer solution and mixed thoroughly.
The resulting solution was then added in a thin stream to 100 mL of 0.1N HCl containing 1% w/v
sodium carboxyl methylcellulose contained in a 250 mL beaker while stirring at 600 rpm to emulsify
the added droplets.
Stirring was continued for 10 min to disperse the added mixture as fine droplets.
The dispersion was transferred to a Buchner flask and stirring was continued with laboratory stirrer.
The solvent was then removed by evaporation at room temperature to produce spherical
microcapsules.
The microcapsules were collected by decantation and washed with water.
The product was then dried at 600 C for 1 h to get discrete microcapsules.
2.3. Characterization of DS microcapsules
2.3.1. Particle Size Distribution
Different sizes of microcapsules in a batch were separated by sieve analysis [11] using a range of standard
sieves (#10, #22, #44, #52 and # 60). The amount retained on different sieves was weighed. From the
obtained data, weight percent retained on different sieves and average size of microcapsules were
calculated.
2.3.2. Shape and surface morphology
The shape and surface morphology of the microcapsules
was studied by using scanning electron microscope. Microcapsules were mounted directly onto the SEM
sample stub using double-sided sticking tape and coated with gold film (thickness 200 nm) under reduced
pressure (0.001 mm of Hg).
2.3.3. Practical yield
The percentage yield of DS in the microencapsulated
product is determined by using the formula,
2.3.4. Percentage drug content
Microcapsules equivalent to 50 mg of DS were weighed accurately and dissolved in the 10 ml of
chloroform. The solution was filtered, diluted suitably and drug content was analyzed at 285 nm by UV
spectrophotometer. Each sample analyzed in triplicate. Percentage drug content was calculated for all
batches using the equation as follows:
2.3.5. Encapsulation efficiency
The encapsulation efficiency of microcapsules was
Calculated by using the formula:
2.3.6. In vitro drug release studies
In vitro release profile for microcapsules as well as pure drug were performed using USP XXII type 2
dissolution apparatus. Sample equivalent to 100 mg of Diclofenac was added to 900mL phosphate buffer of
pH 7.4 at 37±0.5ºC and stirred at 50 rpm. Aliquot of 5 mL was withdrawn at time intervals of 0.25, 0.5,
0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 h. The with drawn volume was replenished with the same volume of
dissolution medium in order to keep the total volume constant. The absorbance of the samples was
measured at λ max 285 nm after suitable dilution if necessary, using phosphate buffer of pH 7.4 as blank.
Results of in vitro drug release studies obtained from absorbance data were tabulated and shown
graphically as Cumulative % drug released V/s Time.
* The percentage practical yield decreased as the concentration of polymer
increased in the formulation. The percentage practical yield was found to be in
the range of 62.84 to 80.85 %. The maximum percentage practical yield was
found to be 80.85% for F-1. The microcapsules of all three batches were found
to be discrete, spherical, free-flowing and of uniform in size. The average size
of microcapsules in various batches was found to be 759.12 μm, 669.97 μm and
758.7 μm for F-1, F-2 and F-3, respectively.
3. RESULTS AND DISCUSSION
4. CONCLUSIONS
Sustained release DS microcapsules could be formulated by
using ethyl cellulose as a release retardant by emulsion solvent
evaporation technique.
The microcapsules of all the formulated batches were spherical,
discrete and free flowing.
The drug content was found to be uniform in a batch of
microcapsules.
Increasing the polymer concentration in microcapsule
formulation decreases the rate of drug release dramatically.
Further, an elaborate in vivo study is to be carried out for the
formulated microcapsule using a suitable animal model.
10
10

More Related Content

PDF
NIOSOME, ITS PREPARATION AND EVALUATION
PPT
Four Levels of In-Vitro-In-Vivo Correlation
PPTX
In-Vivo In-Vitro Correlation
PPTX
Gastro Retentive Drug Delivery System
PPTX
Physics of tablet compression
PPTX
microspheres types , preparation and evaluation
PPTX
Approaches for the design of transdermal drug delivery
PPT
Microencapsulation (2)
NIOSOME, ITS PREPARATION AND EVALUATION
Four Levels of In-Vitro-In-Vivo Correlation
In-Vivo In-Vitro Correlation
Gastro Retentive Drug Delivery System
Physics of tablet compression
microspheres types , preparation and evaluation
Approaches for the design of transdermal drug delivery
Microencapsulation (2)

What's hot (20)

PPT
CONTROLLED DRUG DELIVERY SYSTEMS
PPT
Oral & dissolution controlled release system
PPTX
Preparation & stability of large & small volume parentrals
PPTX
Dissolution
PPTX
Statistical modeling in pharmaceutical research and development
PPTX
Optimization techniques in pharmaceutical formulation and processing
PPTX
IN-VITRO-IN VIVO CORRELATION (IVIVC).pptx
PPT
Dissolution Testing Apparatus
PPT
Liposomes-Classification, methods of preparation and application
PPTX
Theories of dispersion
PPT
PPTX
Dissolution and drug release testing
PDF
FORMULATION AND EVALUATION OF GELATIN MICROSPHERES LOADED WITH FENOFIBRATE
PPT
Dissolution testing
PDF
Non clinical drug development. ppt
PPTX
Microparticle : formulation and evaluation
PPTX
ICH and WHO Guideline for Validation and Calibration.pptx
PPTX
Factorial design M Pharm 1st Yr.
PPTX
Compression and Compaction
PPTX
Preparation and application of Niosomes
CONTROLLED DRUG DELIVERY SYSTEMS
Oral & dissolution controlled release system
Preparation & stability of large & small volume parentrals
Dissolution
Statistical modeling in pharmaceutical research and development
Optimization techniques in pharmaceutical formulation and processing
IN-VITRO-IN VIVO CORRELATION (IVIVC).pptx
Dissolution Testing Apparatus
Liposomes-Classification, methods of preparation and application
Theories of dispersion
Dissolution and drug release testing
FORMULATION AND EVALUATION OF GELATIN MICROSPHERES LOADED WITH FENOFIBRATE
Dissolution testing
Non clinical drug development. ppt
Microparticle : formulation and evaluation
ICH and WHO Guideline for Validation and Calibration.pptx
Factorial design M Pharm 1st Yr.
Compression and Compaction
Preparation and application of Niosomes
Ad

Similar to Evaluation of microencapsulation (20)

PPTX
Formulation and in-vitro Evaluation of Disclofenac Microspheres for Sustained...
PPT
MANUFACTURING EQUIPMENTS,EVALUATION & STABILITY ASPECTS OF MICROCAPSULE
PPTX
MICROCAPSULE/ MICROSPHERES:- TYPES, PREPARATION & EVALUATION
PPTX
Microspheres
PDF
Formulation and evaluation of microspheres
PPTX
Microspheres
PDF
Formulation and evaluation of microspheres with aceclofenac
PPTX
Microsphere microspheres ppt of micros.pptx
PPTX
FORMULATION AND EVALUATION OF GLIBENCLAMIDE MICROSPHERE DRUG DELIVERY SYSTEM
PDF
microsphere and microencapsulation
PDF
DEVELOPMENT & EVALUATION OF MUCOADHESIVE MICROSPHERES OF PIOGLITAZONE MALEATE
PPTX
Microencapsulation
PDF
Formulation and Evaluation of Microspheres Containing Aceclofenac
PDF
Microspheres Preparation and Evaluations.pdf
PPTX
Microspheres Preparation and Evaluations.pptx
PPTX
MicrospheresPreparationandEvaluations.pptx
PPTX
microparticulate drug delivery system ppt
PPTX
Microspheres (2) copy
PPTX
Microspheres (2)
PDF
microencapsulation technology
Formulation and in-vitro Evaluation of Disclofenac Microspheres for Sustained...
MANUFACTURING EQUIPMENTS,EVALUATION & STABILITY ASPECTS OF MICROCAPSULE
MICROCAPSULE/ MICROSPHERES:- TYPES, PREPARATION & EVALUATION
Microspheres
Formulation and evaluation of microspheres
Microspheres
Formulation and evaluation of microspheres with aceclofenac
Microsphere microspheres ppt of micros.pptx
FORMULATION AND EVALUATION OF GLIBENCLAMIDE MICROSPHERE DRUG DELIVERY SYSTEM
microsphere and microencapsulation
DEVELOPMENT & EVALUATION OF MUCOADHESIVE MICROSPHERES OF PIOGLITAZONE MALEATE
Microencapsulation
Formulation and Evaluation of Microspheres Containing Aceclofenac
Microspheres Preparation and Evaluations.pdf
Microspheres Preparation and Evaluations.pptx
MicrospheresPreparationandEvaluations.pptx
microparticulate drug delivery system ppt
Microspheres (2) copy
Microspheres (2)
microencapsulation technology
Ad

More from Institute of Pharmacy, Nirma University (9)

PDF
INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER & INVESTIGATION BROCHURE
PDF
COMPARISON OF COSMETICS REGULATION BETWEEN USFDA VS CDSCO
PDF
History of computers in pharmaceutical research & development
PDF
TOTAL QUALITY MANAGEMENT : A BRIEF
PDF
Aptamers based drug delivery
INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER & INVESTIGATION BROCHURE
COMPARISON OF COSMETICS REGULATION BETWEEN USFDA VS CDSCO
History of computers in pharmaceutical research & development
TOTAL QUALITY MANAGEMENT : A BRIEF
Aptamers based drug delivery

Recently uploaded (20)

PPTX
CME 2 Acute Chest Pain preentation for education
PPT
Management of Acute Kidney Injury at LAUTECH
PPT
Breast Cancer management for medicsl student.ppt
PPTX
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
PPTX
Transforming Regulatory Affairs with ChatGPT-5.pptx
PPTX
Neuropathic pain.ppt treatment managment
PPT
Copy-Histopathology Practical by CMDA ESUTH CHAPTER(0) - Copy.ppt
PPTX
neonatal infection(7392992y282939y5.pptx
PPT
STD NOTES INTRODUCTION TO COMMUNITY HEALT STRATEGY.ppt
PPTX
anaemia in PGJKKKKKKKKKKKKKKKKHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH...
PDF
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
PPTX
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
PPTX
Important Obstetric Emergency that must be recognised
PPTX
Uterus anatomy embryology, and clinical aspects
PDF
Intl J Gynecology Obste - 2021 - Melamed - FIGO International Federation o...
PDF
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
PPTX
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
PPTX
Fundamentals of human energy transfer .pptx
PDF
شيت_عطا_0000000000000000000000000000.pdf
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
CME 2 Acute Chest Pain preentation for education
Management of Acute Kidney Injury at LAUTECH
Breast Cancer management for medicsl student.ppt
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
Transforming Regulatory Affairs with ChatGPT-5.pptx
Neuropathic pain.ppt treatment managment
Copy-Histopathology Practical by CMDA ESUTH CHAPTER(0) - Copy.ppt
neonatal infection(7392992y282939y5.pptx
STD NOTES INTRODUCTION TO COMMUNITY HEALT STRATEGY.ppt
anaemia in PGJKKKKKKKKKKKKKKKKHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH...
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
Important Obstetric Emergency that must be recognised
Uterus anatomy embryology, and clinical aspects
Intl J Gynecology Obste - 2021 - Melamed - FIGO International Federation o...
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
Fundamentals of human energy transfer .pptx
شيت_عطا_0000000000000000000000000000.pdf
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng

Evaluation of microencapsulation

  • 1. EVALUATION OF MICROENCAPSULATION PRESENTED BY :_ MR. ANURAG PDY (B.PHARM) SUBMITTED TO :_ MR.VIPIN AGARWAL ASSOCIATE PROFESSOR AT (INVERTIS INSTITUTE OF PHARMACY)
  • 2. INTRODUCTION Microencapsulation is one of the most interesting modes of drug delivery systems. It is an interdisciplinary field that requires knowledge of field of pure polymer science, familiarity in emulsion technology and an in-depth understanding of drug and protein stabilization. It is a process in which very tiny droplets or particles of liquid or solid material are surrounded or coated with a continuous film of polymeric material, ranging in size from 1 to 5,000 microns. This technique is mainly used for taste masking of bitter drugs, formulation of controlled release and sustained action dosage forms, separation of incompatible materials, protection of moisture and light sensitive drugs. Diclofenac sodium (DS) is a Non-steroidal anti-inflammatory drug (NSAID) belongs to the group of aryl acetic acid derivative. It is widely used in treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. Because of its short biological half-life (2 hrs.), it is eliminated from plasma compartments of the body within few hours, so frequent administration is necessary to maintain its therapeutic concentration. Evaluation of sustained release microcapsules containing Diclofenac sodium
  • 3. (Continued…….) It also known that repeated oral administration of DS in the large doses causes gastrointestinal disturbances, peptic ulcer and bleeding. The usual therapeutic dose and dosing frequency of conventional DS tablets is high, because of the short biological half-life of the drug (2 hrs.); makes it an ideal candidate for modified release dosage forms. To reduce the frequency of administrations and to improve patient compliances, once daily sustained release dosage forms of DS is desirable. The choice of the methods for the preparation of microcapsules depends on many factors such as the drug solubility, partition co-efficiency, polymer composition, molecular weight etc. For instance, emulsion solvent evaporation technique may be a method of choice for the preparation of microspheres of water insoluble drugs. In the emulsion solvent evaporation method, the water insoluble drug and polymer are dissolved in an organic phase, emulsified to form an o/w emulsion, evaporated the organic phase and the microcapsules so formed are filtered and dried. Since Diclofenac is a water insoluble drug, emulsion solvent evaporation technique is selected for the preparation of sustained release microcapsules
  • 4. 2. MATERIALS AND METHODS 2.1. Materials Ethyl cellulose, sodium carboxyl methyl cellulose, chloroform, hydrochloric acid and methanol. All reagents used were of analytical reagent grade. Double distilled water was used for all the experiments. 2.2. Preparation of DS microcapsules DS microcapsules were prepared by emulsion solvent evaporation technique by employing the chloroform as solvent and ethyl cellulose as a polymer with a core: coat ratio of 1:1, 2:3 and 2:1. The polymer (1, 1.5 and 0.5 g) was dissolved in chloroform (25 mL) to form a homogeneous polymer solution. Core material DS (1 g) was added to the polymer solution and mixed thoroughly. The resulting solution was then added in a thin stream to 100 mL of 0.1N HCl containing 1% w/v sodium carboxyl methylcellulose contained in a 250 mL beaker while stirring at 600 rpm to emulsify the added droplets. Stirring was continued for 10 min to disperse the added mixture as fine droplets. The dispersion was transferred to a Buchner flask and stirring was continued with laboratory stirrer. The solvent was then removed by evaporation at room temperature to produce spherical microcapsules. The microcapsules were collected by decantation and washed with water. The product was then dried at 600 C for 1 h to get discrete microcapsules.
  • 5. 2.3. Characterization of DS microcapsules 2.3.1. Particle Size Distribution Different sizes of microcapsules in a batch were separated by sieve analysis [11] using a range of standard sieves (#10, #22, #44, #52 and # 60). The amount retained on different sieves was weighed. From the obtained data, weight percent retained on different sieves and average size of microcapsules were calculated. 2.3.2. Shape and surface morphology The shape and surface morphology of the microcapsules was studied by using scanning electron microscope. Microcapsules were mounted directly onto the SEM sample stub using double-sided sticking tape and coated with gold film (thickness 200 nm) under reduced pressure (0.001 mm of Hg). 2.3.3. Practical yield The percentage yield of DS in the microencapsulated product is determined by using the formula,
  • 6. 2.3.4. Percentage drug content Microcapsules equivalent to 50 mg of DS were weighed accurately and dissolved in the 10 ml of chloroform. The solution was filtered, diluted suitably and drug content was analyzed at 285 nm by UV spectrophotometer. Each sample analyzed in triplicate. Percentage drug content was calculated for all batches using the equation as follows: 2.3.5. Encapsulation efficiency The encapsulation efficiency of microcapsules was Calculated by using the formula:
  • 7. 2.3.6. In vitro drug release studies In vitro release profile for microcapsules as well as pure drug were performed using USP XXII type 2 dissolution apparatus. Sample equivalent to 100 mg of Diclofenac was added to 900mL phosphate buffer of pH 7.4 at 37±0.5ºC and stirred at 50 rpm. Aliquot of 5 mL was withdrawn at time intervals of 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 h. The with drawn volume was replenished with the same volume of dissolution medium in order to keep the total volume constant. The absorbance of the samples was measured at λ max 285 nm after suitable dilution if necessary, using phosphate buffer of pH 7.4 as blank. Results of in vitro drug release studies obtained from absorbance data were tabulated and shown graphically as Cumulative % drug released V/s Time.
  • 8. * The percentage practical yield decreased as the concentration of polymer increased in the formulation. The percentage practical yield was found to be in the range of 62.84 to 80.85 %. The maximum percentage practical yield was found to be 80.85% for F-1. The microcapsules of all three batches were found to be discrete, spherical, free-flowing and of uniform in size. The average size of microcapsules in various batches was found to be 759.12 μm, 669.97 μm and 758.7 μm for F-1, F-2 and F-3, respectively. 3. RESULTS AND DISCUSSION
  • 9. 4. CONCLUSIONS Sustained release DS microcapsules could be formulated by using ethyl cellulose as a release retardant by emulsion solvent evaporation technique. The microcapsules of all the formulated batches were spherical, discrete and free flowing. The drug content was found to be uniform in a batch of microcapsules. Increasing the polymer concentration in microcapsule formulation decreases the rate of drug release dramatically. Further, an elaborate in vivo study is to be carried out for the formulated microcapsule using a suitable animal model.
  • 10. 10 10